BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 29644440)

  • 21. Liquid biopsy and its role in an advanced clinical trial for lung cancer.
    Johann DJ; Steliga M; Shin IJ; Yoon D; Arnaoutakis K; Hutchins L; Liu M; Liem J; Walker K; Pereira A; Yang M; Jeffus SK; Peterson E; Xu J
    Exp Biol Med (Maywood); 2018 Feb; 243(3):262-271. PubMed ID: 29405770
    [TBL] [Abstract][Full Text] [Related]  

  • 22. What do we need to make circulating tumour DNA (ctDNA) a routine diagnostic test in lung cancer?
    Bernabé R; Hickson N; Wallace A; Blackhall FH
    Eur J Cancer; 2017 Aug; 81():66-73. PubMed ID: 28609695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EGFR mutations in lung cancer: from tissue testing to liquid biopsy.
    Fenizia F; De Luca A; Pasquale R; Sacco A; Forgione L; Lambiase M; Iannaccone A; Chicchinelli N; Franco R; Rossi A; Morabito A; Rocco G; Piccirillo MC; Normanno N
    Future Oncol; 2015; 11(11):1611-23. PubMed ID: 26043215
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liquid biopsy using the supernatant of a pleural effusion for EGFR genotyping in pulmonary adenocarcinoma patients: a comparison between cell-free DNA and extracellular vesicle-derived DNA.
    Lee JS; Hur JY; Kim IA; Kim HJ; Choi CM; Lee JC; Kim WS; Lee KY
    BMC Cancer; 2018 Dec; 18(1):1236. PubMed ID: 30526536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Can EGFR mutation status be reliably determined in pre-operative needle biopsies from adenocarcinomas of the lung?
    Lindahl KH; Sørensen FB; Jonstrup SP; Olsen KE; Loeschke S
    APMIS; 2015 Apr; 123(4):289-97. PubMed ID: 25556929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of advanced lung cancer based on genomic profiling using liquid biopsy (plasma): A review of three cases.
    Mitsumura T; Kumaki Y; Takahashi K; Matsudera S; Sakakibara R; Honda T; Ishizuka M; Iijima Y; Shirai T; Okamoto T; Tateishi T; Sakashita H; Miyake S; Ikeda S; Miyazaki Y
    Thorac Cancer; 2021 Sep; 12(18):2508-2512. PubMed ID: 34378333
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sensitive detection of EGFR mutations in cerebrospinal fluid from lung adenocarcinoma patients with brain metastases.
    Yang H; Cai L; Zhang Y; Tan H; Deng Q; Zhao M; Xu X
    J Mol Diagn; 2014 Sep; 16(5):558-563. PubMed ID: 24994671
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Feasibility of cell-free circulating tumor DNA testing for lung cancer.
    Santarpia M; Karachaliou N; González-Cao M; Altavilla G; Giovannetti E; Rosell R
    Biomark Med; 2016; 10(4):417-30. PubMed ID: 26974841
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The liquid biopsy: a tool for a combined diagnostic and theranostic approach for care of a patient with late-stage lung carcinoma presenting with bilateral ocular metastases.
    Bouhlel L; Hofman V; Maschi C; Ilié M; Allégra M; Marquette CH; Audigier-Valette C; Thariat J; Hofman P
    Expert Rev Anticancer Ther; 2017 Dec; 17(12):1087-1092. PubMed ID: 29069959
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EGFR detection by liquid biopsy: ripe for clinical usage.
    Batra U; Nathany S; Sharma M; Jain P; Dhanda S; Singh H; Jain A; Mehta A
    Future Oncol; 2022 Jan; 18(1):85-92. PubMed ID: 34704813
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidermal growth factor receptor mutations in synchronous recurrent lung cancer in an 82-year-old woman. A case story.
    Kristiansen C; Olsen KE; Hansen NC; Hansen KH; Hansen O
    Acta Oncol; 2012 Sep; 51(7):948-9. PubMed ID: 22471746
    [No Abstract]   [Full Text] [Related]  

  • 32. A prospective study of the use of circulating markers as predictors for epidermal growth factor receptor-tyrosine kinase inhibitor treatment in pulmonary adenocarcinoma.
    Luo YH; Tseng PC; Lee YC; Perng RP; Whang-Peng J; Chen YM
    Cancer Biomark; 2016; 16(1):19-29. PubMed ID: 26484608
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liquid biopsy tracking of lung tumor evolutions over time.
    Russo A; De Miguel Perez D; Gunasekaran M; Scilla K; Lapidus R; Cooper B; Mehra R; Adamo V; Malapelle U; Rolfo C
    Expert Rev Mol Diagn; 2019 Dec; 19(12):1099-1108. PubMed ID: 31608732
    [No Abstract]   [Full Text] [Related]  

  • 34. Plasma epidermal growth factor receptor mutation testing with a chip-based digital PCR system in patients with advanced non-small cell lung cancer.
    Kasahara N; Kenmotsu H; Serizawa M; Umehara R; Ono A; Hisamatsu Y; Wakuda K; Omori S; Nakashima K; Taira T; Naito T; Murakami H; Koh Y; Mori K; Endo M; Nakajima T; Yamada M; Kusuhara M; Takahashi T
    Lung Cancer; 2017 Apr; 106():138-144. PubMed ID: 28285688
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Urine circulating-tumor DNA (ctDNA) detection of acquired EGFR T790M mutation in non-small-cell lung cancer: An outcomes and total cost-of-care analysis.
    Sands J; Li Q; Hornberger J
    Lung Cancer; 2017 Aug; 110():19-25. PubMed ID: 28676213
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Emerging Role of "Liquid Biopsies," Circulating Tumor Cells, and Circulating Cell-Free Tumor DNA in Lung Cancer Diagnosis and Identification of Resistance Mutations.
    Esposito A; Criscitiello C; Trapani D; Curigliano G
    Curr Oncol Rep; 2017 Jan; 19(1):1. PubMed ID: 28110461
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Case report: small cell transformation and metastasis to the breast in a patient with lung adenocarcinoma following maintenance treatment with epidermal growth factor receptor tyrosine kinase inhibitors.
    Lin Q; Cai GP; Yang KY; Yang L; Chen CS; Li YP
    BMC Cancer; 2016 Aug; 16():593. PubMed ID: 27488410
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The potential of liquid biopsies.
    Buder A; Tomuta C; Filipits M
    Curr Opin Oncol; 2016 Mar; 28(2):130-4. PubMed ID: 26730486
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transformation to small cell lung cancer as an acquired resistance mechanism in EGFR-mutant lung adenocarcinoma: a case report of complete response to etoposide and cisplatin.
    Hwang KE; Jung JW; Oh SJ; Park MJ; Shon YJ; Choi KH; Jeong ET; Kim HR
    Tumori; 2015 Jun; 101(3):e96-8. PubMed ID: 25908039
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.
    Yu G; Xie X; Sun D; Geng J; Fu F; Zhang L; Wang H
    Int J Clin Exp Pathol; 2015; 8(7):8603-6. PubMed ID: 26339441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.